[Comment] Revisiting RECIST: the case of treatment beyond progression

The use of the standardised Response Evaluation Criteria in Solid Tumors (RECIST) to determine response to novel therapy has been a notable improvement in increasing reproducibility and confidence in the results of clinical trials.1,2 The first RECIST guidelines were published in 2000 and were biased towards identifying progression in ambiguous situations, with a view to preventing unnecessary treatment. RECIST is not based on any particular mechanistic understanding of response to therapy but rather aims to improve reproducibility among observers and reduce measurement error.
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Tags: Comment Source Type: research